All In Biotech

Drug Trial Radar · NCT05601440

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

484

Planned (sponsor's estimate)

Start

Jun 13, 2023

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
First posted
Nov 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is being done to test a sample of blood (or tumour tissue) for biomarkers to see if patients can participate in the study

Conditions

  • Breast Cancer

Interventions

  • RP-6306Drug

    Dose and schedule will be assigned at enrolment

  • GemcitabineDrug

    Dose and schedule will be assigned at enrolment

  • ObservationOther

    Monitoring arm

  • NiraparibDrug

    Dose and schedule will be assigned at enrolment

  • FulvestrantDrug

    Dose and schedule will be assigned at enrolment

  • RP-3500Drug

    Dose and schedule will be assigned at enrolment

  • CFI-402257Drug

    Dose and schedule will be assigned at enrolment

  • CFI-400945Drug

    Dose and schedule will be assigned at enrolment

  • Sacituzumab govitecanDrug

    Dose and schedule will be assigned at enrolment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate whether biomarker selection improves outcomes as assessed by RECIST 1.1 for overall response rateTime frame: 5 years
  2. Evaluate whether biomarker selection improves outcomes as assessed by RECIST 1.1 for clinical benefit rateTime frame: 5 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada · Recruiting

  • BCCA - Kelowna

    Kelowna, British Columbia, Canada · Recruiting

  • BCCA - Vancouver

    Vancouver, British Columbia, Canada · Recruiting

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada · Recruiting

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada · Recruiting

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada · Recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada · Recruiting

  • Odette Cancer Centre

    Toronto, Ontario, Canada · Suspended

  • University Health Network

    Toronto, Ontario, Canada · Recruiting

  • The Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.